公开(公告)号：US20210179626A1

公开(公告)日：2021-06-17

申请号：US17174733

申请日：2021-02-12

Applicant: Genentech, Inc.

Inventor： Mark ZAK ,  F. Anthony ROMERO ,  Po-wai YUEN ,  Emily J. HANAN

IPC: C07D487/04 ,  C07D471/04 ,  C07D491/048 ,  C07D498/04 ,  C07D513/04

Abstract: Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20210171997A1

公开(公告)日：2021-06-10

申请号：US17067059

申请日：2020-10-09

Applicant: Genentech, Inc.

Inventor： Michael W. LAIRD ,  Richard ST. JOHN ,  Jane V. GUNSON ,  Kimberly KALEAS ,  Deepa NADARAJAH ,  Rachel L.E. ADAMS ,  Bradley R. SNEDECOR

IPC: C12P21/00 ,  C07K16/00

Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm. The present invention also contemplates a method of producing a recombinant protein comprising (a) fermenting a menE gene-deleted prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, (b) harvesting said recombinant protein; and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm, and wherein the recombinant protein yield is increased by about 20% or greater.

公开(公告)号：US20210169865A1

公开(公告)日：2021-06-10

申请号：US17178609

申请日：2021-02-18

Applicant: Genentech, Inc. ,  Board of Regents, The University of Texas System

Inventor： Mark Merchant ,  Deepak Sampath ,  Marina Konopleva ,  Lina Han

IPC: A61K31/4523 ,  A61K45/06 ,  A61K31/496 ,  A61P35/02

Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

公开(公告)号：US20210163417A1

公开(公告)日：2021-06-03

申请号：US16921297

申请日：2020-07-06

Applicant: Genentech, Inc.

Inventor： Bryan Chan ,  Joy Drobnick ,  Lewis Gazzard ,  Timothy Heffron ,  Jun Liang ,  Sushant Malhotra ,  Rohan Mendonca ,  Naomi Rajapaksa ,  Craig Stivala ,  John Tellis ,  Weiru Wang ,  BinQing Wei ,  Aihe Zhou ,  Matthew W. Cartwright ,  Michael Lainchbury ,  Emanuela Gancia ,  Eileen Seward ,  Andrew Madin ,  David Favor ,  Kin Chiu Fong ,  Yonghan Hu ,  Andrew Good

IPC: C07D217/22 ,  A61K31/549 ,  A61P35/00 ,  A61K45/06 ,  C07D401/04 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/501 ,  C07D471/04 ,  C07D413/04 ,  C07D413/14 ,  A61K31/5377 ,  C07D417/04 ,  A61K31/4985 ,  C07D401/14 ,  C07D487/04 ,  A61K31/551 ,  C07D498/04 ,  A61K31/5383 ,  C07D405/14 ,  C07D519/00 ,  C07D498/14 ,  C07D513/04 ,  A61K31/554 ,  A61K31/55 ,  A61K31/472 ,  C07D409/14 ,  C07D491/04 ,  C07D487/14

Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

公开(公告)号：US11021711B2

公开(公告)日：2021-06-01

申请号：US15838042

申请日：2017-12-11

Applicant: GENENTECH, Inc.

Inventor： Mark Lackner ,  Lukas C. Amler ,  Guy Cavet ,  Carol O'Brien ,  Ajay Pandita

IPC: C12Q1/6886 ,  C12N15/113 ,  A61K47/68

Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

公开(公告)号：US20210139552A1

公开(公告)日：2021-05-13

申请号：US16998597

申请日：2020-08-20

Applicant: Genentech, Inc.

Inventor： Matthew KALO ,  Timothy Then-Chioh LU ,  Siddharth SUKUMARAN ,  Yehong WANG ,  Peter William DAY

IPC: C07K14/54 ,  A61K45/06 ,  A61P1/04

Abstract: The invention relates to methods, uses, and compositions (e.g., articles of manufacture and kits) for the treatment of diseases associated with IL-22 (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (CD)) and graft versus host disease (GVHD) (e.g., acute or chronic GVHD)).

公开(公告)号：US20210130399A1

公开(公告)日：2021-05-06

申请号：US17145233

申请日：2021-01-08

Applicant: Genentech, Inc.

Inventor： Jefferson C. Emery ,  Paul J. McDonald ,  Rhona O'Leary

IPC: C07K1/18 ,  B01D15/36 ,  C07K16/32 ,  C07K16/28 ,  C07K16/30

Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.

公开(公告)号：US20210115141A1

公开(公告)日：2021-04-22

申请号：US17074471

申请日：2020-10-19

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Juana Elva HERNANDEZ MONTALVO ,  Naseer Ul Din QAYUM ,  Jamie Harue HIRATA

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/7068 ,  A61K31/555 ,  A61K47/68 ,  A61K9/00

Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma (DLBCL)) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody (such as rituximab) and one or more chemotherapeutic agents (such as gemcitabine and oxaliplatin).

公开(公告)号：US20210107895A1

公开(公告)日：2021-04-15

申请号：US17031492

申请日：2020-09-24

Applicant: GENENTECH, INC.

Inventor： Daniel SUTHERLIN ,  Steven MCKERRALL ,  Kwong Wah LAI

IPC: C07D401/14

Abstract: The invention provides a compounds and salts that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.

公开(公告)号：US10966963B2

公开(公告)日：2021-04-06

申请号：US15955539

申请日：2018-04-17

Applicant: Genentech, Inc.

Inventor： Sharada Labadie ,  Jun Liang ,  Daniel Fred Ortwine ,  Xiaojing Wang ,  Jason Zbieg ,  Birong Zhang ,  Simon Charles Goodacre ,  Nicholas Charles Ray ,  Jun Li ,  Tommy Lai ,  Jiangpeng Liao ,  Zhiguo Liu ,  John Wai ,  Tao Wang

IPC: A61K31/437 ,  C07D471/04 ,  A61K31/138 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/506 ,  A61K31/565 ,  A61K45/06

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.